GenEmbryomics Limited (XGEN)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	43.25M
Revenue (ttm)	n/a
Net Income	-1.98M
EPS	-0.22
Shares Out	9.11M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About XGEN

GenEmbryomics is a genomics-based company with a mission dedicated to empowering families to have healthy children by providing in-vitro fertilization patients and providers unparalleled insights into an embryo's genetic disease. Our flagship test Panacea-GenomeScreen™ offers preimplantation genetic testing (“PGT”) via whole genome sequencing (“WGS”) of individuals, couples and IVF embryos. Through our test, which we intend to launch commercially in the third quarter of the fiscal year ended June 30, 2025, IVF clinics can gain an actionable gen...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2019
• Employees: 1
• Stock Exchange: NASDAQ
• Ticker Symbol: XGEN
• Website: https://www.genembryomics.com/en

Financial Performance

Data Source: SEC filings Last updated: Sep 4, 2026

The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.

Data Sources Report a data error